Protective effects of the imidazoline-like drug lnp599 in a marmoset model of obesity-induced metabolic disorders.

Date publication

juin 2021

Journal

International journal of obesity (2005)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MONASSIER Laurent

Tous les auteurs :
Weiss M, Fellmann L, Regnard P, Bousquet P, Monassier L, Niederhoffer N

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33654274

Résumé

Overweight and obesity are undoubtable risk factors for type 2 diabetes and cardiovascular diseases and significantly contribute to the global morbi-mortality. We previoulsy reported that LNP599, a pharmacological imidazoline-like activator of hepatic AMPK/adiponectin signaling, protects against the development of adiposity and obesity and the associated cardio-metabolic disorders, suggesting that it may be a suitable drug candidate for a therapeutic approach targeting the development of obesity at very early stages. The objective of the present study was to evaluate the metabolic effects of LNP599 in a model of diet-induced overweight and metabolic disorders in a nonhuman primate, the common marmoset (Callithrix jacchus), and more particularly to establish the impact of the compound on cholesterol homeostasis, i.e., HDL and LDL/VLDL lipoproteins.

Mots clés

Aniline Compounds, pharmacology, Animals, Body Weight, drug effects, Callithrix, Disease Models, Animal, Imidazolines, Male, Metabolic Diseases, etiology, Obesity, complications, Protective Agents, pharmacology, Pyrroles, pharmacology

Référence

Int J Obes (Lond). 2021 06;45(6):1229-1239